Australia, Sept. 23 -- Convergence Bio Inc., owns the trademark (2565271) for 'CHEMRNA' till July 11, 2035.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations, vaccines and medical therapeutics for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; vaccines for human use; nutritional and dietary supplements for improving the aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; pharmaceutical preparations, vaccines and medical therapeutics for the prevention and treatment of blood disorders, bone disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes] and 42 [Research and development of therapeutic antibodies and pharmaceuticals, and research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; development of pharmaceutical preparations, vaccines and medicines; clinical studies; drug development and discovery; medical research for development of therapeutic modalities for treatment of diseases; assays and reagents for use in scientific and biomedical research; research and development of pharmaceutical preparations, vaccines and therapeutic drugs for the prevention and treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; research and development of therapeutic modalities for treatment of aging nervous system, aging cardiovascular system, aging respiratory system, aging gastrointestinal system, aging reproductive system, aging renal system, aging endocrine system, aging lymphatic system, aging immune system, aging muscular system, aging skeletal system, aging integumentary system, and for boosting energy, boosting vitality, promoting sleep, alleviating anxiety, enhancing memory and cognitive ability, and weight loss; preclinical and clinical development of therapeutic products]
Type of Mark: Word
Date of Acceptance: July 15
Registration Advertised: Sept. 22
For further details contact By George Legal.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2565271.
Disclaimer: Curated by HT Syndication.
